Immunogenicity Assays - Abzena

Immunogenicity Assays

Helping you to better understand your drug candidate.

Start smarter with Abzena.

The evaluation of a drug candidate’s developability is a pivotal stage in the drug development process. Therapeutic antibodies and proteins can induce an immune response. Immunogenicity risk assessment is therefore a crucial aspect of biopharmaceutical drug development. Abzena’s experts offer immunogenicity assays, that help you better understand your drug.

Although the potential for immunogenicity of therapeutic antibodies and proteins has been significantly reduced through the application of protein engineering technologies, clinical data shows that many biopharmaceuticals still induce an immune response in patients. Immunogenicity therefore remains a concern for companies developing new products and for the regulatory agencies asked to approve their use.

Our next-generation EpiScreen® 2.0 platform is Abzena’s innovative answer to these challenges. We utilize flow cytometry technology for precise, multi-dimensional immunogenicity assays. We provide a comprehensive suite of bioassays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.

Smarter immunogenicity testing

When it comes time to evaluate the immunogenic risk of your biopharmaceutical program, our newly enhanced EpiScreen® 2.0 platform offers a comprehensive suite of assays that can predict, and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.

To learn more and access our info sheet click the button below.